Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Heal...( The Laboratory-Developed Test is De...),Health

The Laboratory-Developed Test is Designed to Differentiate Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90

Percent. Accurate Diagnosis is Important for Guiding Treatment. Bevacizumab(1), a Therapy for Non-Squamous NSCLC, Includes a Warning About Potential Higher

Rates of Severe or Fatal Hemorrhage in Patients With Squamous NSCLC

Histology. Once approved by the New York State Department of Health, the Test Will be Available Nationwide Through Columbia University Medical Center's Molecular

Pathology Laboratory, Which Developed and Validated the Test.

REHOVOT, Israe and JERSEY CITY, New Jersey and NEW YORK, April 3 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) and Columbia University Medical Center (CUMC) announced today that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed by CUMC, has been submitted for approval by the New York State Department of Health. The test is designed to differentiate squamous from non-squamous NSCLC and is the first to use this technology to successfully classify two distinct types of the most common form of lung cancer.

Once approved by New York State Department of Health, the test will be made available nationwide through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory, a laboratory licensed to use nucleic acids for better diagnosis of various cancers, which is part of the Department of Pathology and Cell Biology at CUMC.

"With advancements toward more targeted therapies for cancer, there is a growing need for better diagnostics," said Amir Avniel, President and CEO of Rosetta Genomics.

The test, performed on a sample of the patient's tumor and validated by Columbia University Medical Center, classifies sq
'/>"/>